These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 29254534

  • 1. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months).
    Felipe C, Tedesco-Silva H, Ferreira Brigido A, Bessa A, Ruppel P, Hiramoto L, de Paula M, Cristelli M, Stopa S, Mansur J, Viana L, Fahham L, Pepe C, Medina-Pestana J.
    Value Health Reg Issues; 2017 Dec; 14():108-115. PubMed ID: 29254534
    [Abstract] [Full Text] [Related]

  • 2. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Dec; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 3. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 4. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Miranda TA, Felipe CR, Santos RHN, Medina Pestana JO, Tedesco-Silva Junior H.
    Ther Drug Monit; 2020 Dec; 42(6):811-820. PubMed ID: 32657909
    [Abstract] [Full Text] [Related]

  • 5. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P, Felipe C, Ferreira A, Cristelli M, Viana L, Mansur J, Basso G, Hannun P, Aguiar W, Tedesco Silva H, Medina-Pestana J.
    Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
    [Abstract] [Full Text] [Related]

  • 6. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, Mujica-Mota R, Peters J, Varley-Campbell J, Huxley N, Moore J, Allwood M, Lowe J, Hyde C, Hoyle M, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [Abstract] [Full Text] [Related]

  • 7. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 8. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M, Snowsill T, Jones-Hughes T, Crathorne L, Cooper C, Varley-Campbell J, Mujica-Mota R, Coelho H, Huxley N, Lowe J, Dudley J, Marks S, Hyde C, Bond M, Anderson R.
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 10. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

  • 11. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV, Pinheiro PMA, Sales MLMBO, Girão CM, Campos ÉF, Esmeraldo RM.
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [Abstract] [Full Text] [Related]

  • 12. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J, Cristelli MP, Viana LA, Ficher KN, Nakamura MR, Proença H, Dreige YC, de Marco R, de Lima MG, Foresto RD, Aguiar WF, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2024 Jan 01; 108(1):261-275. PubMed ID: 37525373
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May 01; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 14. Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus.
    Nunes Ficher K, Dreige Y, Gessolo Lins PR, Nicolau Ferreira A, Toniato de Rezende Freschi J, Linhares K, Stopa Martins S, Custodio L, Cristelli M, Viana L, Wagner Santos D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Nakamura M, Rosso Felipe C, Medina Pestana J, Tedesco Silva H.
    Transplantation; 2022 Feb 01; 106(2):381-390. PubMed ID: 33988338
    [Abstract] [Full Text] [Related]

  • 15. The Cost of Gastrointestinal Adverse Events and the Impact of Dose-Reductions/Discontinuations on Acute Rejection in Kidney Transplant Patients of Mycophenolate Mofetil-Related Compared to Enteric-Coated Mycophenolate Sodium: A Pharmacoeconomic Study.
    Martinez-Mier G, Salazar-Ramirez A.
    Transplant Proc; 2016 Mar 01; 48(2):588-95. PubMed ID: 27110009
    [Abstract] [Full Text] [Related]

  • 16. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM, Keating GM.
    Drugs; 2003 Mar 01; 63(24):2803-35. PubMed ID: 14664658
    [Abstract] [Full Text] [Related]

  • 17. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T, Okada M, Futamura K, Yamamoto T, Tsujita M, Goto N, Narumi S, Watarai Y, Takeda A, Iwasaki K, Uchida K, Kobayashi T.
    Int Immunopharmacol; 2016 Oct 01; 39():192-198. PubMed ID: 27491025
    [Abstract] [Full Text] [Related]

  • 18. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P, Jouve T, Rostaing L.
    Exp Clin Transplant; 2016 Aug 01; 14(4):361-6. PubMed ID: 27041365
    [Abstract] [Full Text] [Related]

  • 19. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F.
    Trials; 2016 Feb 17; 17():92. PubMed ID: 26888217
    [Abstract] [Full Text] [Related]

  • 20. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A, Iwai T, Uchida J.
    Transplant Proc; 2022 Mar 17; 54(2):293-298. PubMed ID: 35031117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.